Prime Therapeutics Announces New, Cost-Effective Humira® Biosimilar Solutions, Offering Clients Flexibility And Choice ...

The Biologics Price Competition and Innovation Act (BPCIA) of 2010 initially posed significant barriers to biosimilar ...

Blue Shield of California will offer an adalimumab biosimilar at a price that is 75% less than the reference product Humira ...

On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which ...

Sandoz Canada head office and sales force operations certified carbon neutral by LCL Engineering, Environment & Sustainable ...

Biological drugs target specific immune components to manage autoimmune diseases and cancer without suppressing the entire ...

Orum Therapeutics, specializing in degrader-antibody conjugates, has filed for a $67 million IPO on South Korea's Kosdaq. The ...

“Biosimilars are clearly a new and big issue for us,” she said, introducing Westminster Health Form’s Biosimilars in the NHS – Commissioning, Development and Engagement with Clinicians and ...

Per Genentech, the current price of Herceptin for a patient with “HER2 positive metastatic breast cancer” as about $50,000, a ...

Out-of-pocket costs for biosimilars and generics are still high for patients despite these drugs leading to estimated savings ...

Biosimilars are essential but costly treatments that are similar to previously approved biological drugs, making them less ...

pharmaphorum interviews Dr Conrad Savoy on the challenges involved with getting biosimilars and biobetters to market, and also the opportunities they present. Biosimilars and biobetters present a ...